Leerink a buyer of Catamaran ahead of Q2 results Leerink says it's a buyer of Catamaran (CTRX) ahead of the company's Q2 results as it believes shares have more room to run. The firm is cautious on Express Scripts (ESRX) after hearing from a specialist that service challenges may impact the company's 2015 and 2016 selling seasons. The firm remains positive on CVS Caremark (CVS), but notes shares have outperformed and the company could see retail pressure from recent drug inflation trends.
News For CTRX;ESRX;CVS From The Last 14 Days
Check below for free stories on CTRX;ESRX;CVS the last two weeks.